Comparative Effectiveness of First-Line Treatments for Castration-Resistant Prostate Cancer: A Large-Scale Retrospective Study in Japan.

ABSTRACT:

Objectives

Prostate cancer is the fifth leading cause of cancer-related death in men worldwide, with particularly high mortality rates in countries with large Black populations, and the United States. Despite the prevalence of prostate cancer screening, advanced cases are still diagnosed, with 10%-20% of these progressing to castration-resistant prostate cancer (CRPC) within 5 years. The survival of patients with CRPC is limited, which emphasizes the need for effective treatment strategies.

Methods

The study utilized a database of Japanese DPC hospitals, comprising approximately 25.6% coverage. From April 2008 to December 2022, 410,000 patients with prostate cancer were identified, of whom 25,934 were diagnosed with CRPC. A subset of 20,177 patients who received treatment fo

SUBMITTER: Hashizume A 

PROVIDER: S-EPMC12329185 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature